Background illustration for clinical trials search

Paid Clinical Trials Augusta

Discover 151 paid clinical trials in Augusta, Maine. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2

Zanubrutinib and Venetoclax in CLL (ZANU-VEN)

for
Chronic Lymphocytic Leukemia (CLL),
Location: Scarborough ME, Boston MA, South Weymouth MA
Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 18+

Code: NCT05168930

Phase 2, Recruiting

A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

for
Renal Cell Carcinoma
Location: Westbrook ME, Baltimore MD, Charlotte NC, Knoxville TN,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT07227402

Phase 3, Recruiting

Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia

for
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Location: Scarborough ME, Boston MA
Sponsor: Inhye Ahn

Sex: All

Age: 18+

Code: NCT06333262

Phase 2, Recruiting

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

for
Prostate Cancer
Location: Scarborough ME, Boston MA, Cooperstown NY, The Bronx NY,
Sponsor: Novartis Pharmaceuticals

Sex: Male

Age: 18 - 70+

Code: NCT06855277

Phase 3, Recruiting

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

for
HER2-positive Breast Cancer, Breast Cancer
Location: Scarborough ME, Boston MA, New York NY, Camillus NY,
Sponsor: Jazz Pharmaceuticals

Sex: All

Age: 18+

Code: NCT07102381

Phase 2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

for
Triple Negative Breast Cancer
Location: Scarborough ME, Methuen MA, Boston MA,
Sponsor: Gilead Sciences

Sex: All

Age: 18+

Code: NCT05633654

Phase 3, Recruiting

ATEMPT 2.0: Adjuvant T-DM1 vs TH

for
Breast Cancer, HER2-positive Breast Cancer
Location: Scarborough ME, Brewer ME, Portsmouth NH, Concord NH,
Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 18+

Code: NCT04893109

Phase 2, Recruiting

MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

for
Breast Cancer
Location: Portland ME, Albany NY, Waterbury CT, Mount Kisco NY,
Sponsor: Agendia

Sex: All

Age: 18+

Code: NCT03053193

Recruiting

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

for
Breast Neoplasms, Carcinoma, Ductal, Breast,
Location: Westbrook ME, Babylon NY, Morgantown WV,
Sponsor: Natera, Inc.

Sex: All

Age: 18+

Code: NCT07214532

Recruiting

AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors

for
Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR),
Location: Westbrook ME, Toronto, Indianapolis IN, Zion IL,
Sponsor: Amgen

Sex: All

Age: 18 - 70+

Code: NCT07403721

Phase 1, Recruiting

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

for
Breast Neoplasms, Neoplasm Metastasis
Location: Westbrook ME, Lebanon NH, Summit NJ, Bethlehem PA,
Sponsor: Eli Lilly and Company

Sex: All

Age: 18+

Code: NCT07174336

Phase 3, Recruiting

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

for
Breast Neoplasms
Location: Westbrook ME, Quebec, Burlington MA, New York NY,
Sponsor: BioNTech SE

Sex: All

Age: 18+

Code: NCT07173751

Phase 3, Recruiting

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

for
Metastatic Gastric Adenocarcinoma,
Location: Westbrook ME, Florham Park NJ, Flemington NJ,
Sponsor: BeOne Medicines

Sex: All

Age: 18+

Code: NCT07043400

Phase 3, Recruiting

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

for
Carcinoma, Non-Small-Cell Lung
Location: Westbrook ME, Burlington VT, Worcester MA, Hartford CT,
Sponsor: Eli Lilly and Company

Sex: All

Age: 18+

Code: NCT06890598

Phase 3, Recruiting

The THOR IDE Study

for
Peripheral Artery Disease, Peripheral Artery Stenosis,
Location: Portland ME, Providence RI, Fall River MA, New York NY,
Sponsor: Philips Clinical & Medical Affairs Global

Sex: All

Age: 18+

Code: NCT05916950

Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

for
Non-small Cell Lung Cancer
Location: Scarborough ME, Saint John, Montreal, West Haven CT,
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT06692738

Phase 3, Recruiting

EFS of the DUO System for Tricuspid Regurgitation

for
Tricuspid Regurgitation, Tricuspid Valve Insufficiency,
Location: Scarborough ME, Boston MA, Harrisburg PA, Columbus OH,
Sponsor: CroiValve Limited

Sex: All

Age: 18+

Code: NCT05913908

Recruiting

GLP-1R Actions on Muscle and the Skeleton

for
Musculoskeletal Abnormalities, Obesity, Sarcopenic Obesity,
Location: Scarborough ME
Sponsor: Pennington Biomedical Research Center

Sex: All

Age: 18 - 50

Code: NCT07154719

Recruiting

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

for
Non-small Cell Lung Cancer (NSCLC)
Location: South Portland ME, Boston MA, Moncton, Halifax,
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT07291037

Phase 3, Recruiting

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

for
Breast Cancer, Locally Advanced Breast Cancer,
Location: Scarborough ME, Lebanon NH, Burlington MA,
Sponsor: Olema Pharmaceuticals, Inc.

Sex: All

Age: 18+

Code: NCT07085767

Phase 3, Recruiting